EUCTR2017-005067-40-BE进行中（未招募）1 期
Phase II open-label, multicenter, randomized trial of neoadjuvant palbociclib in combination with hormonal therapy and HER2 blockade versus paclitaxel in combination with HER2 blockade for postmenopausal patients with hormone receptor positive/HER2 positive early breast cancer - TOUCH
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 144
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •? Histologically confirmed invasive breast cancer, with the following characteristics:
- •- Early breast cancer with tumor size >1 cm (as measured by at least one of the required examination methods of clinical examination, mammography and ultrasonography)
- •- No clinical evidence of regional lymph node metastasis (via physical and/or radiological exam) (cN0), OR, clinical evidence of cN1 status, defined by nodal involvement limited to clinically detectable metastasis to movable ipsilateral level I, II axillary lymph node(s)
- •- No evidence of metastasis (M0)
- •Postmenopausal, defined by women with:
- •- Prior bilateral surgical oophorectomy; OR
- •- Amenorrhea and age =60 years; OR
- •- Age <60 years and amenorrhea for 12 or more consecutive months in the absence of alternative pathological or physiological cause (including chemotherapy, tamoxifen, toremifene, ovarian suppression, or hormonally-based contraception) plus FSH and serum estradiol levels within the laboratory’s reference ranges for postmenopausal women
- •? Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- •? Primary tumor must have positive estrogen receptor (ER) =10%
- •? Primary tumor must be HER2-positive (by IHC and/or ISH)
- •? Baseline LVEF =55% measured by Echocardiography (preferred) or MUGA scan
- •? Normal hematologic status,
- •- Absolute neutrophil count =1500/mm3 (1.5 × 109/L)
- •- Platelets =100 × 109/L
- •- Hemoglobin =9 g/dL (=90 g/L)
- •? Normal renal function: serum creatinine =1.5 ULN
- •? Normal liver function:
- •- Serum total bilirubin =1.5 × upper limit of normal (ULN). In the case of known Gilbert’s syndrome, a higher serum total bilirubin (<2 × ULN) is allowed
- •- AST or ALT =2.5 × ULN
- •- Alkaline phosphatase =2.5 × ULN
- •? Written Informed Consent (IC) must be signed and dated by the patient and the Investigator prior to randomization.
- •? The patient has been informed of and agrees to data transfer and handling, in accordance with national data protection guidelines.
- •? The patient agrees in writing to make tumor (mandatory diagnostic core biopsy and surgical specimen) available for submission for central pathology review and to conduct translational studies as part of this protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 72
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 72
排除标准
- •- Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or skin nodules) (T4 according to AJCC 8th edition cancer staging TNM)
- •- Inflammatory breast cancer
- •- Bilateral invasive breast cancer
- •- Received any prior treatment for primary invasive breast cancer
- •- Any active tumor of non-breast-cancer histology
- •- Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina pectoris, ongoing cardiac dysrhythmias of NCI CTCAE grade =2, atrial fibrillation of any grade, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (NYHA functional classification =II), cerebrovascular accident including transient ischemic attack, or symptomatic pulmonary embolism
- •- Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject’s safety
- •- Contraindications or known hypersensitivity to any of the trial medications or excipients
- •- Treatment with any investigational agents within 30 days prior to expected start of trial treatment
- •- Any GI disorder that may affect absorption of oral medications, such as malabsorption syndrome or status post major bowel resection
- •- Evidence via physical and/or radiological exam of cN2 or cN3 nodal involvement defined by: metastasis to ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted, OR involvement of ipsilateral infraclavicular, internal mammary and/or supraclavicular lymph node(s)
- •- History of extensive disseminated / bilateral or known presence of interstitial fibrosis or interstitial lung disease, including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, obliterative bronchiolitis, and pulmonary fibrosis. A history of prior radiation pneumonitis is not considered an exclusion criterion.
研究者
相似试验
进行中（未招募）
1 期
A research study to reduce the use of chemotherapy in breast cancer treatment.Post menopausal patients with histologically confirmed estrogen receptor positive, HER2 positive primary breast cancerMedDRA version: 23.0Level: LLTClassification code 10070575Term: Estrogen receptor positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 23.0Level: PTClassification code 10065430Term: HER2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-005067-40-ITINTERNATIONAL BREAST CANCER STUDY GROUP144
进行中（未招募）
1 期
Phase II, multicenter, randomized, open-label study with MAP +/- denosumab regimen for the treatment of patients with metastatic osteosarcomaEUCTR2021-002366-41-ITASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA112
招募中
1 期
Phase II, multicenter, randomized, open-label study of premenopausal women with luminal breast cancer investigating the effect of elacestrant (oral selective estrogen receptor degrader) with/without triptorelin on the estrogen receptor functional pathway and Ki67 proliferation. Preoperative trial - PremiÈRe.CTIS2023-503373-37-01Solti Group48
进行中（未招募）
1 期
Evaluation of the safety and efficacy of avelumab addition to the standard chemotherapy (carboplatin-gemcitabine) in urothelial carcinoma treatmentnresectable or metastatic urothelial carcinoma in patients without prior systemic therapy and who are ineligible to receive cisplatin-based therapyMedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864EUCTR2017-004260-36-ESAssociació Per a la Recerca Oncològica (APRO)80
进行中（未招募）
不适用
Phase 2, randomised, open label, multicenter study of intradermal IMA901 plus GM-CSF with or without low dose cyclophosphamide pre-treatment in advanced renal cell carcinoma patients with measurable diseaseHLA-A*02-positive patients with advanced clear cell RCC who have progressed during or after previous systemic therapy for advanced disease and have a favourable or intermediate risk after systemic therapy according to the 3-score risk cc prognostic risk category (Motzer 2004).EUCTR2006-006370-25-ATimmatics biotechnologies GmbH72